Supported through an unrestricted educational grant
from Novo Nordisk Pharmaceuticals, Inc.
 

The Basics of Continuous Subcutaneous Insulin Infusion Therapy

Program Goal

This continuing education monograph is designed to introduce the reader to the concepts of intensive glycemic control in patients with diabetes mellitus using continuous subcutaneous insulin infusion (CSII). The intent of the monograph is to provide the reader with a review of basic information about CSII to enable them to take the first step toward becoming a certified insulin pump trainer or member of an insulin pump support team. The basics of CSII therapy and patient education and the skills and knowledge needed to fulfill the important role of counseling patients about the benefits and use of CSII are reviewed.

Target Audience

This continuing education monograph is designed for registered nurses and pharmacists who treat patients with diabetes and wish to expand their knowledge of insulin therapy and CSII.

Educational Objectives

Upon successful completion of this educational activity, the reader should be able to:

  • Describe the importance of intensive glycemic control
  • Describe the basic mechanism of CSII therapy

  • Describe the intent and indications for CSII therapy

  • Discuss the benefits and risks associated with CSII therapy

  • Describe the process for selecting, training, and initiating patients to CSII therapy
  • Discuss the types of insulin used in CSII therapy
  • Discuss the material, financial, and psychosocial resources necessary for successful CSII therapy

Commercial Support

This continuing education activity is supported by an unrestricted educational grant from Novo Nordisk Pharmaceuticals, Inc.

Pharmacists

Novo Nordisk Pharmaceuticals, Inc., is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program has been assigned the Universal Program Number (360-999-01-001-H01) and is acceptable for 2 credits (0.2 CEUs) in states that recognize ACPE-approved providers.

In order to receive a statement of credit online, participants must read the entire monograph, complete the evaluation form, and score at least 70% on the learning assessment.

Nurses

This educational activity for 2.5 contact hours is provided by Postgraduate Institute for Medicine (PIM). PIM is approved as a provider of continuing education in nursing by the Colorado Nurses Association, which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

In order to receive a statement of credit online, participants must read the entire monograph, complete the evaluation form, and score at least 70% on the learning assessment.

Fee

There is no fee to receive credits for this program.

Release Date and Time for Completion

This activity was originally released on November 1, 2001. This activity will expire on November 1, 2004 for pharmacists and nurses.

Editorial Review Board

John B. Buse, MD, PhD, CDE
Chief, Division of General Internal Medicine
Director, Diabetes Care Center
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Dr. Buse disclosed the following financial relationships: Grants/Research Support/Speakers Bureau for Eli Lilly and Co. and Novo Nordisk Pharmaceuticals, Inc., Consultant for Eli Lilly and Co., and Honorarium from Eli Lilly and Co., Novo Nordisk Pharmaceuticals, Inc., and MiniMed, Inc.

Thomas S. Sisca, PharmD, FCCP, BCPS
Clinical Manager, Pharmacy
Memorial Hospital
Easton, Maryland

Dr. Sisca disclosed that he has no financial relationships to report.

Jane Young, RN, BSN, CDE, CPT
Diabetes Care Center
Genesis Medical Center
Davenport, Iowa

Ms. Young disclosed that she has no financial relationships to report.

Disclosure Declaration

It is the policy of Novo Nordisk Pharmaceuticals, Inc. and Postgraduate Institute for Medicine (PIM) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with the commercial companies whose products or devices may be mentioned in the activity or with the supporter of this continuing education activity. The information is for participant information; it is not assumed that these relationships will have a negative impact on the content of the activity.

Disclaimers

  • Approval of credit for this continuing education program does not imply endorsement by Postgraduate Institute for Medicine (PIM) of any product or manufacturer identified.
  • Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
  • This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA).
  • Novo Nordisk Pharmaceuticals, Inc., Postgraduate Institute for Medicine (PIM), and the activity's faculty do not endorse the use of any product in a manner that is not approved by the FDA.

    The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Trademarks

Animas R-1000 is a registered trademark of Animas Corporation. Disetronic Insulin Infusion Pumps are trademarks of Disetronic Medical Systems, Inc. Deltec Cozmo is a trademark of Deltec, Inc. Humulin is a registered trademark of Eli Lilly and Company. Lente, Ultralente, Novolin, NovoLog, and Velosulin BR are registered trademarks of Novo Nordisk A/S. MiniMed, MiniMed 508, MiniMed Paradigm, Sof-set, Square Wave, and Dual Wave are registered trademarks of Medtronic MiniMed. DANA Diabecare II is a registered trademark of DanaDiabecare USA.

Pharmacists Click Here to Continue

Nurses Click Here to Continue

 

Copyright© 2001, Novo Nordisk Pharmaceuticals, Inc. All rights reserved.

No part of this program may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, electrostatic, magnetic tape, mechanical, photocopying, recording, or otherwise) without permission from Novo Nordisk Pharmaceuticals, Inc. Published by Health Answers Inc., 1140 Welsh Road, Suite 100, North Wales, PA 19454


For our Terms of Use and Privacy Policy, please review our Legal Agreement.
Copyright© 2004 CECity® All rights reserved.

 

HOME | HELP | EMAIL

NOTE: All of the tables and figures require Adobe Acrobat Reader

Click here to download Adobe Acrobat Reader for FREE

NOTE: All of the tables and figures require Adobe Acrobat Reader

Click here to download Adobe Acrobat Reader for FREE